
    
      In this retrospective cohort study the safety of RefortrixTM (Tdap) administered during
      pregnancy as part of the National immunization program in Brazil will be assessed by
      comparing the risk of pre-defined adverse events before and after introduction of the
      RefortrixTM (Tdap) maternal immunization program.
    
  